July/August #173 : New and Improved Treatment for Hep C - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Sisters Act

The Anal Dialogues

From the Editor

Ass-Backward

Feedback

Letters- July/August 2011

The POZ Q+A

Volunteer Mission

What You Need to Know

Kramer Makes Hearts Pound on Broadway

Nearly 7 Out of 10 Young People Are Having Sex

Film About Positive Kids Prevents HIV in Thailand

HIV Wasn’t a Motive for Triple Ax Murder

Angels Travel on Horseback in Southern Africa

Showcasing HIV Stigma in China

HIV Is (Officially) a Disability

96 Percent

We Hear You

Lips Unsealed

What Matters to You

How to Age With HIV—Gracefully

Treatment News

Help for Peripheral Neuropathy

HIV-Positive? Get Screened for Anal Cancer

Isolation Hurts Health

New and Improved Treatment for Hep C

MRSA Monster Tamed

Too Little Vitamin D Might Hurt Your Heart

IL-7

Comfort Zone

Between the Covers

POZ Heroes

Each One, Reach One

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

July / August 2011

New and Improved Treatment for Hep C

by Laura Whitehorn

In the mid-1990s, protease inhibitors and combo therapy revolutionized HIV treatment, making it more effective and easier to take. Now hepatitis C’s moment is arriving, as new meds and strategies promise to improve therapy, even for people with hard-to-treat genotype 1.
  • New drugs: The FDA has approved two hep C protease inhibitors—Incivek (telaprevir) and Victrelis (boceprevir). Both promise to make standard treatment shorter for many and more effective for most. Alisporivir is the first in another new class, cyclophilin inhibitors, to get past the first clinical trials. All these must be taken with the standard interferon/ribavirin regimen.
  • Improved interferon: An experimental interferon—Peg-Interferon lambda (IFN λ)—appears to be more effective and cause fewer side effects than standard pegylated interferon alpha. (Both must be taken with ribavirin.)
  • Treatment without interferon: Several experimental drug combos look good in very early trials, attacking hep C without the standard pegylated interferon/ribavirin.
  • Statins: Combining a cholesterol-lowering drug (fluvastatin/Lescol did best) with standard hep C therapy improved people’s responses.
Get details and more at hepmag.com or search "Treatment Transformation" on poz.com  news.

Search: Hepatitis C, hep C, genotype 1, Incivek, telaprevir, Victrelis, boceprevir, Alisporivir, cyclophilin inhibitors, interferon, Peg Interferon lambda, ribavirin


Scroll down to comment on this story.

email print



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    InDefaultOf
    Seattle
    Washington


    ernienyc
    Bronx
    New York


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.